<code id='ABF3F48FD5'></code><style id='ABF3F48FD5'></style>
    • <acronym id='ABF3F48FD5'></acronym>
      <center id='ABF3F48FD5'><center id='ABF3F48FD5'><tfoot id='ABF3F48FD5'></tfoot></center><abbr id='ABF3F48FD5'><dir id='ABF3F48FD5'><tfoot id='ABF3F48FD5'></tfoot><noframes id='ABF3F48FD5'>

    • <optgroup id='ABF3F48FD5'><strike id='ABF3F48FD5'><sup id='ABF3F48FD5'></sup></strike><code id='ABF3F48FD5'></code></optgroup>
        1. <b id='ABF3F48FD5'><label id='ABF3F48FD5'><select id='ABF3F48FD5'><dt id='ABF3F48FD5'><span id='ABF3F48FD5'></span></dt></select></label></b><u id='ABF3F48FD5'></u>
          <i id='ABF3F48FD5'><strike id='ABF3F48FD5'><tt id='ABF3F48FD5'><pre id='ABF3F48FD5'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:knowledge    Page View:91

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In